Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope

Ryusuke Omiya, Chantal Buteau, Hiroya Kobayashi, Carlos V. Paya, Esteban Celis

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid, organ transplant patients.

Original languageEnglish (US)
Pages (from-to)2172-2179
Number of pages8
JournalJournal of Immunology
Volume169
Issue number4
DOIs
StatePublished - Aug 15 2002
Externally publishedYes

Fingerprint

Human Herpesvirus 4
Lymphoproliferative Disorders
Epitopes
T-Lymphocytes
Transplants
Peptides
Subunit Vaccines
B-Cell Lymphoma
Immunosuppressive Agents
Immunity
B-Lymphocytes
Vaccines
Transplantation
Alleles
Population
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope. / Omiya, Ryusuke; Buteau, Chantal; Kobayashi, Hiroya; Paya, Carlos V.; Celis, Esteban.

In: Journal of Immunology, Vol. 169, No. 4, 15.08.2002, p. 2172-2179.

Research output: Contribution to journalArticle

Omiya, Ryusuke ; Buteau, Chantal ; Kobayashi, Hiroya ; Paya, Carlos V. ; Celis, Esteban. / Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope. In: Journal of Immunology. 2002 ; Vol. 169, No. 4. pp. 2172-2179.
@article{f7c754dd836e431c98ffadddfc717849,
title = "Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope",
abstract = "Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50{\%}) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid, organ transplant patients.",
author = "Ryusuke Omiya and Chantal Buteau and Hiroya Kobayashi and Paya, {Carlos V.} and Esteban Celis",
year = "2002",
month = "8",
day = "15",
doi = "10.4049/jimmunol.169.4.2172",
language = "English (US)",
volume = "169",
pages = "2172--2179",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope

AU - Omiya, Ryusuke

AU - Buteau, Chantal

AU - Kobayashi, Hiroya

AU - Paya, Carlos V.

AU - Celis, Esteban

PY - 2002/8/15

Y1 - 2002/8/15

N2 - Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid, organ transplant patients.

AB - Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid, organ transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=0037103364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037103364&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.169.4.2172

DO - 10.4049/jimmunol.169.4.2172

M3 - Article

C2 - 12165547

AN - SCOPUS:0037103364

VL - 169

SP - 2172

EP - 2179

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -